Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950M

August 26, 2025

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances

August 19, 2025

Bayer and Kumquat Biosciences to develop and commercialize KRAS G12D inhibitor

August 19, 2025

Pilatus Biosciences and Roche to Evaluate PLT012 in First-in-Human Study in HCC

August 19, 2025

Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer

August 19, 2025

Discovery research reduced to support registrational trials for ORIC-944 and ORIC-114

August 19, 2025

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

August 19, 2025

CIT Therapeutics Forms Strategic Partnership with IFLI, Securing Up to $2.5M to Advance Novel Cancer Therapies

August 19, 2025

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+ for metastatic breast cancer, prostate cancer, and other cancers

August 19, 2025

XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics

August 12, 2025

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes 

August 12, 2025

SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

August 12, 2025

Strand Therapeutics Raises $153M Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline

August 12, 2025

NeOnc Technologies Awarded $2.5M in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia in Ph 2 trials

August 12, 2025

USPTO Grants New Patent for Bexmarilimab Targeting Clever-1 Positive Cancers

August 12, 2025

ViroCell Biologics and AvenCell Therapeutics to accelerate development of novel allogeneic CAR-T therapies for blood cancers

August 5, 2025

Everest Medicines Expands Strategic Investment in I-MAB

August 5, 2025

LIfT BioSciences granted €12M from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy

August 5, 2025

AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program

August 5, 2025

ARTBIO Announces $132 Million Series B Financing to Advance Pipeline of Alpha RLTs and Expand Manufacturing and Supply Chain Infrastructure

August 5, 2025

iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences

July 29, 2025

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines including oncology

July 29, 2025

Development of CY-101 for Cancers Driven by Dysfunction of Wnt/β-catenin Signalling to be Advanced Under International Nonproprietary Name of Getacatetide

July 29, 2025

Dispatch Bio Launches to Deliver Universal Treatment Across Solid Tumors with Novel Immunotherapy Approach

July 29, 2025

Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for ADCs

July 29, 2025
Page1 … Page10 Page11 Page12 Page13 Page14 … Page42

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.